CARE1 is growing in the UK!
New participating site now open:
• Royal Free London
Expanding access to our EU-funded phase III pragmatic trial addressing a key question in 1L mRCC:
IO-IO or IO-TKI?
#clinicalresearch #oncology #RCC #clinicaltrials #care1pct #care1project @ikccorg.bsky.social
New participating site now open:
• Royal Free London
Expanding access to our EU-funded phase III pragmatic trial addressing a key question in 1L mRCC:
IO-IO or IO-TKI?
#clinicalresearch #oncology #RCC #clinicaltrials #care1pct #care1project @ikccorg.bsky.social
June 2, 2026 at 1:56 PM
CARE1 is growing in the UK!
New participating site now open:
• Royal Free London
Expanding access to our EU-funded phase III pragmatic trial addressing a key question in 1L mRCC:
IO-IO or IO-TKI?
#clinicalresearch #oncology #RCC #clinicaltrials #care1pct #care1project @ikccorg.bsky.social
New participating site now open:
• Royal Free London
Expanding access to our EU-funded phase III pragmatic trial addressing a key question in 1L mRCC:
IO-IO or IO-TKI?
#clinicalresearch #oncology #RCC #clinicaltrials #care1pct #care1project @ikccorg.bsky.social
CARE1 is growing in the Netherlands 🇳🇱
New participating sites now open:
• Maastricht UMC+
• Leiden University Medical Center
Expanding access to our EU-funded phase III pragmatic trial tackling a key question in 1L mRCC:
IO-IO or IO-TKI?
#clinicaltrials #oncology #RCC #care1project #care1pct
New participating sites now open:
• Maastricht UMC+
• Leiden University Medical Center
Expanding access to our EU-funded phase III pragmatic trial tackling a key question in 1L mRCC:
IO-IO or IO-TKI?
#clinicaltrials #oncology #RCC #care1project #care1pct
June 2, 2026 at 1:52 PM
CARE1 is growing in the Netherlands 🇳🇱
New participating sites now open:
• Maastricht UMC+
• Leiden University Medical Center
Expanding access to our EU-funded phase III pragmatic trial tackling a key question in 1L mRCC:
IO-IO or IO-TKI?
#clinicaltrials #oncology #RCC #care1project #care1pct
New participating sites now open:
• Maastricht UMC+
• Leiden University Medical Center
Expanding access to our EU-funded phase III pragmatic trial tackling a key question in 1L mRCC:
IO-IO or IO-TKI?
#clinicaltrials #oncology #RCC #care1project #care1pct
CARE1 PI's at ASCO 2026 🔬
IO-IO or IO-TKI in 1L mRCC?
We still lack biomarkers to guide treatment choice.
👉 CARE1, an EU-funded phase III pragmatic trial, is the only head-to-head randomized study addressing this key question.
#ASCO2026 #clinicaltrials #oncology #care1project #care1pct
IO-IO or IO-TKI in 1L mRCC?
We still lack biomarkers to guide treatment choice.
👉 CARE1, an EU-funded phase III pragmatic trial, is the only head-to-head randomized study addressing this key question.
#ASCO2026 #clinicaltrials #oncology #care1project #care1pct
June 2, 2026 at 1:36 PM
CARE1 PI's at ASCO 2026 🔬
IO-IO or IO-TKI in 1L mRCC?
We still lack biomarkers to guide treatment choice.
👉 CARE1, an EU-funded phase III pragmatic trial, is the only head-to-head randomized study addressing this key question.
#ASCO2026 #clinicaltrials #oncology #care1project #care1pct
IO-IO or IO-TKI in 1L mRCC?
We still lack biomarkers to guide treatment choice.
👉 CARE1, an EU-funded phase III pragmatic trial, is the only head-to-head randomized study addressing this key question.
#ASCO2026 #clinicaltrials #oncology #care1project #care1pct
🇩🇪 Another important milestone for #CARE1!
The first patient has been enrolled in Germany. This achievement reflects the commitment and collaboration of German investigators, study teams and coordinators.
#ClinicalResearch #CancerResearch #ClinicalTrials #Germany #CARE1PCT
The first patient has been enrolled in Germany. This achievement reflects the commitment and collaboration of German investigators, study teams and coordinators.
#ClinicalResearch #CancerResearch #ClinicalTrials #Germany #CARE1PCT
September 4, 2026 at 2:19 PM
🇩🇪 Another important milestone for #CARE1!
The first patient has been enrolled in Germany. This achievement reflects the commitment and collaboration of German investigators, study teams and coordinators.
#ClinicalResearch #CancerResearch #ClinicalTrials #Germany #CARE1PCT
The first patient has been enrolled in Germany. This achievement reflects the commitment and collaboration of German investigators, study teams and coordinators.
#ClinicalResearch #CancerResearch #ClinicalTrials #Germany #CARE1PCT
🇧🇪 Belgium continues to strengthen the CARE1 network!
We are delighted to announce the activation of 7 Belgian sites in the CARE1 pragmatic clinical trial.
#CARE1PCT #CARE1Project #ClinicalTrials #Oncology
We are delighted to announce the activation of 7 Belgian sites in the CARE1 pragmatic clinical trial.
#CARE1PCT #CARE1Project #ClinicalTrials #Oncology
July 10, 2026 at 1:06 PM
🇧🇪 Belgium continues to strengthen the CARE1 network!
We are delighted to announce the activation of 7 Belgian sites in the CARE1 pragmatic clinical trial.
#CARE1PCT #CARE1Project #ClinicalTrials #Oncology
We are delighted to announce the activation of 7 Belgian sites in the CARE1 pragmatic clinical trial.
#CARE1PCT #CARE1Project #ClinicalTrials #Oncology
🇳🇱 Welcome to LUMC!
We are pleased to announce the activation of
@LUMC_Leiden
as a participating site in the CARE1 pragmatic clinical trial.
LUMC becomes the 6th active CARE1 site in the Netherlands.
#CARE1PCT #CARE1Project #ClinicalTrials #Oncology
We are pleased to announce the activation of
@LUMC_Leiden
as a participating site in the CARE1 pragmatic clinical trial.
LUMC becomes the 6th active CARE1 site in the Netherlands.
#CARE1PCT #CARE1Project #ClinicalTrials #Oncology
July 9, 2026 at 12:58 PM
🇳🇱 Welcome to LUMC!
We are pleased to announce the activation of
@LUMC_Leiden
as a participating site in the CARE1 pragmatic clinical trial.
LUMC becomes the 6th active CARE1 site in the Netherlands.
#CARE1PCT #CARE1Project #ClinicalTrials #Oncology
We are pleased to announce the activation of
@LUMC_Leiden
as a participating site in the CARE1 pragmatic clinical trial.
LUMC becomes the 6th active CARE1 site in the Netherlands.
#CARE1PCT #CARE1Project #ClinicalTrials #Oncology
🇨🇿 The CARE1 network continues to expand!
We are pleased to announce the activation of a new site in the Czech Republic:
@FNPlzen
#CARE1 #ClinicalTrials #CancerResearch #CARE1PCT
We are pleased to announce the activation of a new site in the Czech Republic:
@FNPlzen
#CARE1 #ClinicalTrials #CancerResearch #CARE1PCT
July 8, 2026 at 2:00 PM
🇨🇿 The CARE1 network continues to expand!
We are pleased to announce the activation of a new site in the Czech Republic:
@FNPlzen
#CARE1 #ClinicalTrials #CancerResearch #CARE1PCT
We are pleased to announce the activation of a new site in the Czech Republic:
@FNPlzen
#CARE1 #ClinicalTrials #CancerResearch #CARE1PCT
🇩🇪 CARE1 reaches a new milestone!
We are delighted to announce that Germany is now open for participation in the CARE1 pragmatic clinical trial.
Thank you to the National Coordinating Center: University Hospital Essen for making this happen!
#CARE1 #ClinicalTrials #CancerResearch #Oncology #CARE1PCT
We are delighted to announce that Germany is now open for participation in the CARE1 pragmatic clinical trial.
Thank you to the National Coordinating Center: University Hospital Essen for making this happen!
#CARE1 #ClinicalTrials #CancerResearch #Oncology #CARE1PCT
July 7, 2026 at 4:53 PM
🇩🇪 CARE1 reaches a new milestone!
We are delighted to announce that Germany is now open for participation in the CARE1 pragmatic clinical trial.
Thank you to the National Coordinating Center: University Hospital Essen for making this happen!
#CARE1 #ClinicalTrials #CancerResearch #Oncology #CARE1PCT
We are delighted to announce that Germany is now open for participation in the CARE1 pragmatic clinical trial.
Thank you to the National Coordinating Center: University Hospital Essen for making this happen!
#CARE1 #ClinicalTrials #CancerResearch #Oncology #CARE1PCT